An SGLT2 inhibitor, canagliflozin, reduces blood glucose level in the renal capillaries and protects the capillary network in the diabetic rats

Documenti analoghi

• Risk of acute pancreatitis with DPP ‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation
  di: Takashi Tatewaki, et al.
  Pubblicazione: (2026)
• SGLT2 inhibitors are associated with a reduced incidence of atrial fibrillation in type 2 diabetes mellitus
  di: Mark Luedde, et al.
  Pubblicazione: (2025)
• Clinical characteristics and outcomes of diabetes‐related ketoacidosis ( DKA ) in sodium‐glucose co‐transporter‐2 inhibitor ( SGLT2i ) users with type 2 diabetes
  di: Angelica Sharma, et al.
  Pubblicazione: (2025)
• Predictors of diabetic ketoacidosis in patients with insulin‐deficient diabetes phenotype initiating SGLT2 inhibitors
  di: Anat Tsur, et al.
  Pubblicazione: (2025)
• Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia
  di: Kaori Ikeda, et al.
  Pubblicazione: (2025)